According to the research report titled ‘Global Monoclonal Antibodies Market 2022-2028’, available with MarketStudyReport, global monoclonal antibodies market is expected to grow at 10.2% CAGR during the review period and generate revenues worth USD 108 billion by 2028.

The expansion of global monoclonal antibodies market is driven by several factors such as rising prevalence of chronic ailments, surging demand for cost-effective treatments, and the presence of well-established healthcare infrastructure in cohorts with supportive government initiatives. 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/5042720/  

For those who are unfamiliar, antibodies are proteins used by the immune system to recognize and neutralize foreign elements such as viruses, bacteria, and tumor cells. Similarly, monoclonal antibodies are laboratory-created molecules that have an equivalent capacity as the immune system to combat bacteria and treat chronic ailments such as macular degeneration, cancer, cardiovascular disease, and so on.

Moreover, massive investments employed in the research & development of such therapies, combined with the emergence of the latest technologies prompting new-age treatments like next-generation sequencing are further escalating global monoclonal antibodies industry development. 

In terms of product type, the market is split into humanized monoclonal antibodies, chimeric monoclonal antibodies, murine monoclonal antibodies, and human monoclonal antibodies. Of these, the human monoclonal antibodies segment held a major market share in 2021.  

Based on manufacturing process, the marketplace is divided into microbial fermentation and mammalian cell culture. With respect to indication, the industry is categorized into inflammatory diseases, cancer, infectious diseases, autoimmune diseases,
and others. 

As per application spectrum, the business sphere is segregated into research, therapeutic, and diagnostic. While end-user ambit is classified into research institutes, hospitals, and others. 

From a geographical perspective, worldwide monoclonal antibodies market spans across North America, Europe, and Asia Pacific.

The companies augmenting the competitive spirit in the market include GlaxoSmithKline plc, AbbVie, Inc., Eli Lilly & Company, Bristol Myers Squibb, Amgen, Inc., AstraZeneca plc, Johnson & Johnson, Daiichi Sankyo Co., Ltd., F. Hoffmann-La Roche AG, Novartis AG, and Merck & Co., Inc. among others.